PMID- 36930965
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230822
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Linking)
VI  - 76
IP  - 6
DP  - 2023 Jun 1
TI  - Natural History of Anemia and Efficacy and Safety of Oral Iron Therapy in 
      Children Newly Diagnosed With Inflammatory Bowel Disease.
PG  - 771-775
LID - 10.1097/MPG.0000000000003764 [doi]
AB  - OBJECTIVES: Anemia is one of the most common extraintestinal manifestations of 
      pediatric inflammatory bowel disease (IBD). We aimed to evaluate the prevalence 
      of anemia in children newly diagnosed with IBD and assess the efficacy and safety 
      of oral iron therapy over a 12-month follow-up period. METHODS: This 
      single-center, retrospective, observational cohort study included all children 
      newly diagnosed with IBD at the Pediatric Gastroenterology Unit of Sapienza 
      University of Rome from May 2015 to May 2019 presenting with anemia. At baseline, 
      demographic, clinical, laboratory data (hemoglobin, mean corpuscular volume, 
      serum iron, ferritin, transferrin levels, erythrocyte sedimentation rate, and 
      C-reactive protein), and treatment received, were recorded. Clinical and 
      laboratory data, as well as anemia therapy and adverse events (AEs), were 
      collected every 3 months during the 1-year follow-up. RESULTS: Eighty-nine out of 
      140 patients newly diagnosed with IBD presented with anemia (64%); 13 were 
      excluded due to incomplete follow-up, thus 76 were included [median age 12.7 
      (interquartile range 9.8-15), 25 (33%) Crohn disease, 51 (67%) ulcerative 
      colitis]. All patients received sucrosomial iron (SI) alone or in combination 
      with intravenous ferric carboxymaltose. Treatment with SI was effective in 67 
      (88%) patients at the end of follow-up [37 (48%) within 3 months], regardless of 
      anemia severity at baseline. No serious AEs related to SI treatment were 
      reported. CONCLUSIONS: We confirmed a high prevalence of anemia at the time of 
      the diagnosis of pediatric IBD. Our data suggest that SI is safe and effective, 
      leading to anemia resolution in approximately half of the patients within 3 
      months.
CI  - Copyright (c) 2023 by European Society for European Society for Pediatric 
      Gastroenterology, Hepatology, and Nutrition and North American Society for 
      Pediatric Gastroenterology, Hepatology, and Nutrition.
FAU - D'Arcangelo, Giulia
AU  - D'Arcangelo G
AD  - From Department of Maternal and Child Health, Pediatric Gastroenterology and 
      Liver Unit, Sapienza University of Rome - Umberto I Hospital, Rome, Italy.
FAU - Distante, Manuela
AU  - Distante M
FAU - Veraldi, Silvio
AU  - Veraldi S
FAU - Tarani, Francesca
AU  - Tarani F
FAU - Musto, Francesca
AU  - Musto F
FAU - Aloi, Marina
AU  - Aloi M
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230316
PL  - United States
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
RN  - 0 (sucrosomial iron)
RN  - 0 (Ferric Compounds)
RN  - E1UOL152H7 (Iron)
RN  - 0 (Hemoglobins)
SB  - IM
MH  - Humans
MH  - Child
MH  - Retrospective Studies
MH  - *Anemia, Iron-Deficiency/drug therapy/etiology
MH  - *Inflammatory Bowel Diseases/complications/drug therapy
MH  - Ferric Compounds/adverse effects
MH  - *Anemia/diagnosis
MH  - Iron/adverse effects
MH  - Hemoglobins/metabolism
COIS- The authors report no conflicts of interest.
EDAT- 2023/03/18 06:00
MHDA- 2023/05/22 06:42
CRDT- 2023/03/17 18:12
PHST- 2023/05/22 06:42 [medline]
PHST- 2023/03/18 06:00 [pubmed]
PHST- 2023/03/17 18:12 [entrez]
AID - 00005176-202306000-00014 [pii]
AID - 10.1097/MPG.0000000000003764 [doi]
PST - ppublish
SO  - J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):771-775. doi: 
      10.1097/MPG.0000000000003764. Epub 2023 Mar 16.